A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

NCT06699212 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

412

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

COMBINATION_PRODUCT: ASP-1929 Photoimmunotherapy
BIOLOGICAL: Pembrolizumab
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: 5-fluorouracil
DRUG: Paclitaxel
DRUG: Docetaxel

Sponsor

Rakuten Medical, Inc.